share_log

United Therapeutics | 10-Q: Q2 2024 Earnings Report

United Therapeutics | 10-Q: Q2 2024 Earnings Report

美國聯合醫療 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/07/31 03:34

Moomoo AI 已提取核心訊息

United Therapeutics reported strong Q2 2024 financial results with total revenues increasing 20% to $714.9 million, driven by robust growth in Tyvaso product sales. Total Tyvaso revenues, including Tyvaso DPI and nebulized Tyvaso, grew 25% year-over-year to $398.2 million, benefiting from increased patient adoption and price increases.Operating income remained stable at $319.9 million compared to $313.4 million in Q2 2023, despite higher operating expenses. Research and development expenses increased 57% to $139.6 million, while selling, general and administrative expenses rose 37% to $177.6 million, primarily due to increased legal expenses and personnel costs.The company maintained a strong financial position with $4.3 billion in cash and investments as of June 30, 2024. During the quarter, United Therapeutics executed a $1 billion accelerated share repurchase program and reduced its credit facility balance to $500 million. The company continues to advance its pipeline, including Phase 3 trials for nebulized Tyvaso in IPF and PPF indications, as well as organ manufacturing initiatives.
United Therapeutics reported strong Q2 2024 financial results with total revenues increasing 20% to $714.9 million, driven by robust growth in Tyvaso product sales. Total Tyvaso revenues, including Tyvaso DPI and nebulized Tyvaso, grew 25% year-over-year to $398.2 million, benefiting from increased patient adoption and price increases.Operating income remained stable at $319.9 million compared to $313.4 million in Q2 2023, despite higher operating expenses. Research and development expenses increased 57% to $139.6 million, while selling, general and administrative expenses rose 37% to $177.6 million, primarily due to increased legal expenses and personnel costs.The company maintained a strong financial position with $4.3 billion in cash and investments as of June 30, 2024. During the quarter, United Therapeutics executed a $1 billion accelerated share repurchase program and reduced its credit facility balance to $500 million. The company continues to advance its pipeline, including Phase 3 trials for nebulized Tyvaso in IPF and PPF indications, as well as organ manufacturing initiatives.
美國聯合醫療公佈了強勁的2024年第二季度財務業績，總收入增長20%，達到71490萬，主要得益於Tyvaso產品銷售的強勁增長。總Tyvaso收入（包括Tyvaso DPI和霧化Tyvaso）同比增長25%，達到39820萬，受益於患者採用率提高和價格上漲。儘管營業費用增加，營業收入仍保持穩定，達到31990萬，而2023年第二季度爲31340萬。研究與開發費用增加57%，達到13960萬，而銷售、一般和行政費用則增加37%，達到17760萬，主要由於法律費用和人事成本的增加。截至2024年6月30日，公司保持了強健的財務狀況，擁有43億的現金和投資。在本季度，美國聯合醫療執行了一項10億加速股份回購計劃，並將其信貸額度餘額減少至50000萬。公司還繼續推進管道項目，包括霧化Tyvaso在特發性肺纖維化（IPF）和稀有肺病（PPF）適應症的三期臨牀試驗，以及器官制造的舉措。
美國聯合醫療公佈了強勁的2024年第二季度財務業績，總收入增長20%，達到71490萬，主要得益於Tyvaso產品銷售的強勁增長。總Tyvaso收入（包括Tyvaso DPI和霧化Tyvaso）同比增長25%，達到39820萬，受益於患者採用率提高和價格上漲。儘管營業費用增加，營業收入仍保持穩定，達到31990萬，而2023年第二季度爲31340萬。研究與開發費用增加57%，達到13960萬，而銷售、一般和行政費用則增加37%，達到17760萬，主要由於法律費用和人事成本的增加。截至2024年6月30日，公司保持了強健的財務狀況，擁有43億的現金和投資。在本季度，美國聯合醫療執行了一項10億加速股份回購計劃，並將其信貸額度餘額減少至50000萬。公司還繼續推進管道項目，包括霧化Tyvaso在特發性肺纖維化（IPF）和稀有肺病（PPF）適應症的三期臨牀試驗，以及器官制造的舉措。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！